Oasmia Pharmaceutical

OverviewSuggest Edit

Oasmia Pharmaceutical develops, manufactures, markets, and sells drugs in the field of human and veterinary oncology. It focuses on manufacturing formulations and drug-delivery systems based on cytostatics. The Company's approved products include Paclical/Apealea, treating cancers, such as lung, breast, and ovarian cancer; and Paccal Vet, a formulation for the treatment of squamous cell carcinoma and mammary carcinoma in dogs. It develops a number of candidates to treat cancer comprising leukemia, prostate, lung, breast cancer, and lymphoma. The Company also develops a formulation to treat lymphoma in dogs.

TypePublic
Founded1990
HQUppsala, SE
Websiteoasmia.com

Latest Updates

Employees (est.) (Jul 2019)55(-3%)
Share Price (Jun 2019)$4.3 (-8%)

Key People/Management at Oasmia Pharmaceutical

Sven Rohmann

Sven Rohmann

CEO
Anette Sjödin

Anette Sjödin

CBO, Deputy CEO
Nina Heldring

Nina Heldring

Chief Medical Officer
Mikael Asp

Mikael Asp

CTO
Dzianis Babrou

Dzianis Babrou

Head of Product Development
Show more

Oasmia Pharmaceutical Office Locations

Oasmia Pharmaceutical has an office in Uppsala
Uppsala, SE (HQ)
Vallongatan 1
Show all (1)

Oasmia Pharmaceutical Financials and Metrics

Oasmia Pharmaceutical Revenue

Market capitalization (5-Jun-2019)

319.0m

Closing stock price (5-Jun-2019)

4.3
Oasmia Pharmaceutical's current market capitalization is $319 m.
Show all financial metrics

Oasmia Pharmaceutical Online and Social Media Presence

Embed Graph

Oasmia Pharmaceutical News and Updates

OASMIA DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Oasmia Pharmaceutical AB To Contact The Firm

New York, NY - (NewMediaWire) - September 20, 2019 - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Oasmia Pharmaceutical AB (“Oasmia” or the “Company”) (NASDAQ: OASM) of the September 27, 2019 deadline to seek the role of lead plaintiff in a federal secu…

The Nomination Committees proposal regarding Board of Directors and auditor of Oasmia Pharmaceutical AB for AGM 2019

Oasmia’s Nomination Committee has informed the company of its proposal regarding Board of Directors and auditor ahead of the Annual General Meeting September 26, 2019.read more

ROSEN, A HIGHLY RANKED LAW FIRM, Reminds Oasmia Pharmaceutical AB Investors of September 27th Deadline in First Filed Securities Class Action Commenced by the Firm

NEW YORK, Aug. 31, 2019 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Oasmia Pharmaceutical AB from October 23, 2015 through July 9, 2019, inclusive (the "Class Period") of the important September 27, 2019 lead plaintiff...

Notice of Annual General Meeting in Oasmia Pharmaceutical AB

This is an unofficial in-house translation of the Swedish original. In case of differences the Swedish version shall prevail.

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Oasmia Pharmaceutical AB To Contact The Firm

New York City, NY - (NewMediaWire) - August 15, 2019 - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Oasmia Pharmaceutical AB (“Oasmia”) (or the “Company”) (NASDAQ: OASM) of the September 27, 2019 deadline to seek the role of lead plaintiff in a federal …
Show more

Oasmia Pharmaceutical Blogs

Notice of extraordinary general meeting in Oasmia Pharmaceutical AB

The shareholders of Oasmia Pharmaceutical AB (the “Company”) are hereby given notice of the extraordinary general meeting on Wednesday 6 November 2019, at 14:00 CET, at the offices of the Company, Vallongatan 1, 752 28 Uppsala. The registration opens at 13:30 CET. NOTICE OF ATTENDANCE Shareholders w…

The Board of Directors in Oasmia proposes a rights issue of approximately SEK 400 million

The Board of Directors in Oasmia Pharmaceutical AB (”Oasmia” or the ”Company”) today announces a notice to an extra general meeting on 6 November 2019. It is proposed that the extra general meeting resolves to authorise the Board of Directors to carry out a rights issue of approximately SEK 400 mill…

Annual General Meeting in Oasmia Pharmaceutical AB on September 26, 2019

This is an unofficial in-house translation of the Swedish original. In case of differences the Swedish version shall prevail. Today, September 26, 2019, Oasmia Pharmaceutical AB (publ) held its Annual General Meeting (AGM) which resolved, among other things, what is summarized below. The AGM adopted…

Oasmia publishes report on special investigation of liability issues conducted by audit firm Deloitte

In connection with Oasmia’s year-end report in June 2019, the company’s Board of Directors made a decision to engage a special examiner, audit firm Deloitte (Svante Forsberg responsible investigator), to investigate the former Board’s responsibilities in a number of issues that has been highlighted …

Oasmia presents Q1 report through audiocast on September 26

Oasmia will hold an audiocast and telephone conference on Thursday 26 September at 10:00 (CET) to present the company’s Q1 report for the financial year 2019/2020. The presentation of the Q1 report will be in English. Presenters will be Jörgen Olsson, Chairman of the Board, and Sven Rohmann, interim…

The Nomination Committee’s proposal regarding Board of Directors and auditor of Oasmia Pharmaceutical AB for AGM 2019

Oasmia’s Nomination Committee has informed the company of its proposal regarding Board of Directors and auditor ahead of the Annual General Meeting September 26, 2019. The Nomination Committee proposes Hege Hellström and Anders Härfstrand as new board members. In addition, the nomination committee p…
Show more

Oasmia Pharmaceutical Frequently Asked Questions

  • When was Oasmia Pharmaceutical founded?

    Oasmia Pharmaceutical was founded in 1990.

  • Who are Oasmia Pharmaceutical key executives?

    Oasmia Pharmaceutical's key executives are Sven Rohmann, Anette Sjödin and Nina Heldring.

  • How many employees does Oasmia Pharmaceutical have?

    Oasmia Pharmaceutical has 55 employees.

  • Who are Oasmia Pharmaceutical competitors?

    Competitors of Oasmia Pharmaceutical include Patterson Companies, MolMed and Akrevia Therapeutics.

  • Where is Oasmia Pharmaceutical headquarters?

    Oasmia Pharmaceutical headquarters is located at Vallongatan 1, Uppsala.

  • Where are Oasmia Pharmaceutical offices?

    Oasmia Pharmaceutical has an office in Uppsala.

  • How many offices does Oasmia Pharmaceutical have?

    Oasmia Pharmaceutical has 1 office.